The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

By Lisa A. Carey, E. Dees, L. Sawyer, Lisa Gatti, D. Moore, F. Collichio, D. Ollila, Carolyn I. Sartor, M. Graham, Charles M. Perou. Clinical Cancer Research, 2007

2,077 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/4cca6486e0bc324df22feb5c69d24566666c62d8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. J. Reis-Filho
2. Aleix Prat
3. Jane E. Visvader
4. Ian O. Ellis
5. Charles M. Perou

In Oncology

1. Aleix Prat
2. J. Reis-Filho
3. Anurag Singh
4. Charles M. Perou
5. Jane E. Visvader
6. A. Damjanović
7. M. Nedeljković
8. J. Settleman

In Pathology and Forensic Medicine

1. Aleix Prat
2. J. Reis-Filho
3. Ian O. Ellis
4. Jane E. Visvader

Citations in the corpus

• An overview of triple-negative breast cancer (2016, background): “Unfortunately, responses to systemic therapy lack durability, and prognosis is inferior compared to other subtypes [74, 105].”
• EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer (2010, result): “However, some reports also suggest that basal, mesenchymal-like cancers are initially more sensitive to neoadjuvant chemotherapy than epithelial luminal tumors (Yauch et al., 2005; Paik et al., 2006; Carey et al., 2007; Liedtke et al., 2008).”
• Deconstructing the molecular portraits of breast cancer (2010, methodology): “In Carey et al. (2007), 107 patients were treated with neoadjuvant AC for 4 cycles and followed for a median of 39 months.”
• Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer—How We Can Rise to the Challenge (2019, background): “On the whole, TNBC patients have a significantly worse overall survival compared to those suffering from non-TNBC breast tumors despite better pCR rates; a phenomenon termed “triple negative paradox” [11].”
• Basal-like breast cancer: a critical review. (2008, methodology): “…but in HDCT, BLC showed marked improvement of outcome that is not different from luminal class BLC showed better response to HDCT than non-BLC Carey et al, 2007 61 Retrospective, nonrandomized study of patients who received neoadjuvant CT (matched cohort) All patients received doxorubicin…”